Ifp Advisors, Inc Regeneron Pharmaceuticals, Inc. Transaction History

Ifp Advisors, Inc

$2.42 Billion
Q2 2024

A detailed history of Ifp Advisors, Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 551 shares of REGN stock, worth $406,638. This represents 0.02% of its overall portfolio holdings.

Number of Shares

551

Previous 505 9.11%

Holding current value

$406,638

Previous $486,000 19.14%

% of portfolio

0.02%

Previous 0.02%

35 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$883.2 - $1071.19 $40,627 - $49,274	46 Added 9.11%	551 $579,000
Q1 2024 Jul 30, 2024	BUY	$902.69 - $993.35 $14,443 - $15,893	16 Added 3.27%	505 $486,000
Q4 2023 Jan 09, 2024	BUY	$775.18 - $881.7 $36,433 - $41,439	47 Added 10.63%	489 $429,000
Q3 2023 Oct 12, 2023	BUY	$692.45 - $844.37 $27,005 - $32,930	39 Added 9.68%	442 $363,000
Q2 2023 Aug 04, 2023	BUY	$700.03 - $830.35 $30,801 - $36,535	44 Added 12.26%	403 $289,000
Q1 2023 Apr 18, 2023	SELL	$680.49 - $826.97 $504,243 - $612,784	-741 Reduced 67.36%	359 $294,000
Q4 2022 Feb 07, 2023	SELL	$705.89 - $766.39 $312,709 - $339,510	-443 Reduced 28.71%	1,100 $364,000
Q3 2022 Nov 08, 2022	BUY	$573.97 - $724.32 $36,734 - $46,356	64 Added 4.33%	1,543 $589,000
Q2 2022 Sep 06, 2022	BUY	$548.35 - $738.84 $811,009 - $1.09 Million	1,479 New	1,479 $561,000
Q2 2022 Aug 12, 2022	SELL	$548.35 - $738.84 $811,009 - $1.09 Million	-1,479 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$595.12 - $698.43 $602,261 - $706,811	1,012 Added 216.7%	1,479 $1.03 Million
Q1 2022 Aug 08, 2022	BUY	$595.12 - $698.43 $9,521 - $11,174	16 Added 3.55%	467 $326,000
Q4 2021 Jan 12, 2022	SELL	$543.48 - $670.97 $38,043 - $46,967	-70 Reduced 13.44%	451 $285,000
Q3 2021 Oct 06, 2021	BUY	$574.03 - $680.96 $9,184 - $10,895	16 Added 3.17%	521 $313,000
Q2 2021 Jul 13, 2021	BUY	$472.8 - $558.54 $95,505 - $112,825	202 Added 66.67%	505 $283,000
Q1 2021 Apr 30, 2021	BUY	$446.73 - $548.2 $14,295 - $17,542	32 Added 11.81%	303 $140,000
Q4 2020 Jan 25, 2021	BUY	$478.3 - $607.98 $43,047 - $54,718	90 Added 49.72%	271 $126,000
Q3 2020 Oct 29, 2020	BUY	$544.75 - $658.21 $10,350 - $12,505	19 Added 11.73%	181 $101,000
Q2 2020 Aug 05, 2020	SELL	$493.32 - $643.92 $7,399 - $9,658	-15 Reduced 8.47%	162 $102,000
Q1 2020 May 12, 2020	BUY	$336.18 - $494.43 $59,503 - $87,514	177 New	177 $80,000
Q4 2019 Jan 17, 2020	SELL	$274.13 - $376.51 $605,279 - $831,334	-2,208 Closed	0 $0
Q3 2019 Nov 07, 2019	BUY	$273.46 - $318.39 $596,963 - $695,045	2,183 Added 8732.0%	2,208 $598,000
Q1 2019 May 15, 2019	SELL	$372.08 - $439.57 $98,229 - $116,046	-264 Reduced 91.35%	25 $10,000
Q4 2018 Jan 23, 2019	SELL	$335.82 - $403.04 $9,738 - $11,688	-29 Reduced 9.12%	289 $107,000
Q3 2018 Oct 25, 2018	BUY	$351.14 - $408.51 $3,511 - $4,085	10 Added 3.25%	318 $0
Q2 2018 Aug 07, 2018	BUY	$284.6 - $344.99 $16,222 - $19,664	57 Added 22.71%	308 $0
Q1 2018 Jun 03, 2019	SELL	$315.82 - $393.78 $38,214 - $47,647	-121 Reduced 32.53%	251 $94,000
Q1 2018 May 09, 2018	BUY	$315.82 - $393.78 $38,214 - $47,647	121 Added 48.21%	372 $0
Q4 2017 Jan 24, 2018	SELL	$358.63 - $469.95 $50,208 - $65,793	-140 Reduced 35.81%	251 $0
Q3 2017 Oct 30, 2017	BUY	$431.38 - $504.0 $2,588 - $3,024	6 Added 1.56%	391 $175,000
Q2 2017 Jun 03, 2019	BUY	N/A	96 Added 33.22%	385 $189,000
Q1 2017 Jun 03, 2019	SELL	N/A	-13 Reduced 4.3%	289 $112,000
Q4 2016 Jun 03, 2019	SELL	N/A	-26 Reduced 7.93%	302 $111,000
Q2 2016 Jun 03, 2019	BUY	N/A	303 Added 1212.0%	328 $115,000
Q1 2016 Jun 03, 2019	BUY	N/A	25	25 $10,000

Others Institutions Holding REGN

# of Institutions

1,531

Shares Held

84.1M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $79.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account